THE SST2 BIOMARKER AS A PREDICTOR OF ADVERSE CLINICAL OUTCOMES IN HEART FAILURE. LITERATURE REVIEW
Introduction. In recent years, there has been a growing number of studies aimed at identifying and evaluating novel biomarkers of cardiovascular diseases, particularly heart failure. This trend is driven by the need to enhance diagnostic accuracy, risk stratification, and personalized treatment approaches. Among these biomarkers, special attention is given to the soluble form of the ST2 receptor (sST2), which has demonstrated significant prognostic value across various forms of heart failure. This review focuses on the analysis of current data regarding the clinical relevance of sST2 and the prospects for its implementation in routine medical practice.
Aim. Analysis of literature data on the biomarker sST2 as a predictor of adverse clinical outcomes in patients with heart failure.
Search Strategy. A literature search was conducted using the scientific databases PubMed, Web of Science, and Google Scholar, as well as electronic scientific libraries eLibrary and CyberLeninka. The search covered a five-year period (2019–2024) and focused on cardiorenal biomarkers as predictors of adverse outcomes in cardiovascular diseases.
Results. This literature review analyzes studies on the prognostic significance of the sST2 biomarker in patients with heart failure. The findings indicate that sST2 reflects key pathophysiological processes, including myocardial fibrosis and systemic inflammation. Evidence from the literature suggests that the integration of sST2 into clinical assessment improves early identification of patients at risk, refines prognostic accuracy, and facilitates ongoing patient monitoring. The integration of this biomarker into clinical practice offers opportunities for more precise risk stratification and a personalized approach to treatment.
Conclusions. A review of contemporary literature on clinical and laboratory predictors of heart failure demonstrates that the biomarker sST2 has high diagnostic and prognostic significance. It reflects myocardial fibrosis and systemic inflammation—processes closely associated with the progression of heart failure. Further research is needed to determine optimal threshold values, validate assessment methodologies, and integrate sST2 into standardized clinical algorithms.
Anar D. Kozhabayeva- PhD, Doctoral student at the Department of Therapy of the NAO "Semey Medical University", Postal address: 103 Abai Kunanbayev str., Semey, 071400, Republic of Kazakhstan, Abay region, https://orcid.org/0000-0003-4132-6755, e-mail:anik97.kz@bk.ru; Phone number: +7 705 817 9617,
Aisulu S. Zhunuspekova - PhD, Acting Associate Professor of the Department of Therapy of the NAO "Semey Medical University", Postal address: 071400, Republic of Kazakhstan, Abai region, Semey, Abai Kunanbayeva str., 103, https://orcid.org/0000-0002-2413-317Х , e-mail: aisulu.zhunuspekova@smu.edu.kz ; Phone number: +7 771 840 5880,
Andrey Yu. Orekhov - PhD, Assistant Professor at the Department of Therapy of the NAO "Semey Medical University", Postal address: 103 Abai Kunanbayeva str., Semey, 071400, Republic of Kazakhstan, Abay region, Semey, https://orcid.org/0000-0001-7201-1399, e-mail: orekhov-andrei@list.ru ; Phone number: +7 777 414 1476,
Assel A. Kassymova – PhD candidate, Department of Therapy of the NAO "Semey Medical University", Postal address: 103 Abai Kunanbayeva str., Semey, 071400, Republic of Kazakhstan, Abay region, Semey, https://orcid.org/0000-0001-9333-4146, e-mail: kassymova2411@gmail.com; Phone number: +7 775 177 4490
Bolat A. Ashirov - Candidate of Medical Sciences, South Kazakhstan Medical Academy, Republic of Kazakhstan, https://orcid.org/0000-0003-0242-9700, e-mail: bolat.baja@mail.
Zhanargyl K. Smailova - Candidate of Medical Sciences, Associate Professor, Vice Rector for Academic and Educational Work, NCJSC «Semey Medical University», phone 8 707 365 82 71, e-mail: zhanargul.smailova@smu.edu.kz; https://orcid.org/0000-0002-4513-4614;
Mirgul A. Kapakova - Candidate of Medical Sciences, Head of the Department of Therapy at the NAO "Semey Medical University", Postal address: 103 Abai Kunanbayev str., Semey, 071400, Republic of Kazakhstan, Abay region, https://orcid.org/0000-0003-4186-8933, e-mail: kma_mira@mail.ru; Phone number: +7 777 278 9724,
Nailya M. Urazalina - Candidate of Medical Sciences, Associate Professor of the Department of physiological disciplines named after honored scientist of the republic of Kazakhstan, professor T.A. Nazarova, NJSC "Semey Medical University", Semey, Kazakhstan; phone: 8 777 907 55 89, е-mail: hakim_15@mail.ru, https://orcid.org/0000-0003-0200-1763,
Lyudmila K. Karazhanova - Doctor of Medical Sciences, Professor of the Department of Therapy of the NAO "Semey Medical University", Postal address: 103 Abai Kunanbayev str., Semey, 071400, Republic of Kazakhstan, Abay region, https://orcid.org/0000-0002-4719-6034, e-mail: kar_ludmila@bk.ru; Phone number: +7 701 355 9976,
*Correspondence author:
Jamilya A. Mansurova - PhD, Associate Professor, Head of the Department of Therapy at the NAO "Semey Medical University", Semey, Kazakhstan,
Postal code: Republic of Kazakhstan, 071400, Semey city, Abay region, Abay Street 103. 071400.
E-mail: mansurova_dzhami@mail.ru
Phone: +7 777 330 5104,
1. Aimo A. [и др.]. Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure // JACC: Heart Failure. 2017. № 4 (5). C. 287–296.
2. Aimo A. [и др.]. Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis // JACC: Heart Failure. 2017. № 4 (5). C. 280–286.
3. Aleksova A. [и др.]. Cardiac Biomarkers in the Emergency Department: The Role of Soluble ST2 (sST2) in Acute Heart Failure and Acute Coronary Syndrome—There is Meat on the Bone // Journal of Clinical Medicine. 2019. № 2 (8). C. 270.
4. Asferg C.L. [и др.]. Relative atrial natriuretic peptide deficiency and inadequate renin and angiotensin II suppression in obese hypertensive men // Hypertension. 2013. № 1 (62). C. 147–153.
5. Bayes-Genis A. [и др.]. Soluble ST2 Serum Concentration and Renal Function in Heart Failure // Journal of Cardiac Failure. 2013. № 11 (19). C. 768–775.
6. Bayes-Genis A. Ordonez-Llanos J. Multiple biomarker strategies for risk stratification in heart failure. Clinica Chimica Acta. 2015. (443). C. 120–125.
7. Boisot S. [и др.]. Serial Sampling of ST2 Predicts 90-Day Mortality Following Destabilized Heart Failure. Journal of Cardiac Failure. 2008. № 9 (14). C. 732–738.
8. Buyzere M.L. De Multi-biomarker risk stratification in heart failure: a story of diminished marginal returns after Herculean efforts? European Journal of Heart Failure. 2018. № 2 (20). C. 278–280.
9. Chen Y. [и др.]. sST2 and Big ET-1 as Alternatives of Multi-Biomarkers Strategies for Prognosis Evaluation in Patients Hospitalized with Heart Failure. International Journal of General Medicine. 2023. (16). C. 5003.
10. Chen Z.H. [и др.]. Correlation of serum homocysteine and cystatin C levels with prognosis in heart failure with preserved ejection fraction patients // BMC Cardiovascular Disorders. 2024. № 1 (24). C. 510.
11. Chirinos J. A. [и др.]. Multiple Plasma Biomarkers for Risk Stratification in Patients with Heart Failure and Preserved Ejection Fraction. Journal of the American College of Cardiology. 2020. № 11 (75). C. 1281.
12. Cong X., Kong W. Endothelial tight junctions and their regulatory signaling pathways in vascular homeostasis and disease. Cellular Signalling. 2020. (66). C. 109485.
13. Conrad N. [и др.]. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet (London, England). 2018. № 10120 (391). C. 572.
14. Conrad N. [и др.]. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet (London, England). 2018. № 10120 (391). C. 572.
15. Demissei B.G. [и др.]. A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. European Journal of Heart Failure. 2017. № 8 (19). C. 1001–1010.
16. Dudek M. [и др.]. sST2 and Heart Failure—Clinical Utility and Prognosis. Journal of Clinical Medicine. 2023. № 9 (12). C. 3136.
17. Dupuy A.M. [и др.]. Multi-Marker Strategy in Heart Failure: Combination of ST2 and CRP Predicts Poor Outcome. PLoS ONE. 2016. № 6 (11). C. e0157159.
18. Emdin M. [и др.]. sST2 Predicts Outcome in Chronic Heart Failure Beyond NT−proBNP and High-Sensitivity Troponin T. Journal of the American College of Cardiology. 2018. № 19 (72). C. 2309–2320.
19. Emdin M. [и др.]. sST2 Predicts Outcome in Chronic Heart Failure Beyond NT−proBNP and High-Sensitivity Troponin T. Journal of the American College of Cardiology. 2018. № 19 (72). C. 2309–2320.
20. Emdin M. [и др.]. sST2 Predicts Outcome in Chronic Heart Failure Beyond NT−proBNP and High-Sensitivity Troponin T. Journal of the American College of Cardiology. 2018. № 19 (72). C. 2309–2320.
21. Fan J. [и др.]. Higher serum sST2 is associated with increased left atrial low-voltage areas and atrial fibrillation recurrence in patients undergoing radiofrequency ablation. Journal of Interventional Cardiac Electrophysiology. 2022. № 3 (64). C. 733–742.
22. Felker G.M. [и др.]. Soluble ST2 in Ambulatory Patients with Heart Failure Association with Functional Capacity and Long-Term Outcomes. Circulation: Heart Failure. 2013. № 6 (6). C. 1172–1179.
23. Gaggin H. K. [и др.]. Head-to-Head Comparison of Serial Soluble ST2, Growth Differentiation Factor-15, and Highly-Sensitive Troponin T Measurements in Patients With Chronic Heart Failure. JACC: Heart Failure. 2014. № 1 (2). C. 65–72.
24. Gimbrone M.A., García-Cardeña G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circulation research. 2016. № 4 (118). C. 620.
25. Gruson D. [и др.]. Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction. International Journal of Cardiology. 2014. № 1 (172). C. e250–e252.
26. Heidenreich P.A. [и др.]. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022. № 18 (145). C. E895–E1032.
27. Homsak E., Gruson D. Soluble ST2: A complex and diverse role in several diseases // Clinica Chimica Acta. 2020. (507). C. 75–87.
28. Januzzi J. L. [и др.]. Measurement of the Interleukin Family Member ST2 in Patients With Acute Dyspnea: Results From the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) Study. Journal of the American College of Cardiology. 2007. № 7 (50). C. 607–613.
29. Januzzi J. L., Mebazaa A., Somma S. Di ST2 and prognosis in acutely decompensated heart failure: The international ST2 consensus panel. American Journal of Cardiology. 2015. № 7 (115). C. 26B-31B.
30. Jones N. R. [и др.]. Survival of patients with chronic heart failure in the community: a systematic review and meta‐analysis. European Journal of Heart Failure. 2019. № 11 (21). C. 1306.
31. Jones N.R. [и др.]. Survival of patients with chronic heart failure in the community: a systematic review and meta‐analysis. European Journal of Heart Failure. 2019. № 11 (21). C. 1306.
32. Kakkar R., Lee R.T. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nature reviews. Drug discovery. 2008. № 10 (7). C. 827.
33. Kalstad A.A. [и др.]. Biomarkers of ageing and cardiac remodeling are associated with atrial fibrillation. Scandinavian Cardiovascular Journal. 2021. № 4 (55). C. 213–219.
34. Kercheva M. [и др.]. Serum Soluble ST2 and Adverse Left Ventricular Remodeling in Patients With ST-Segment Elevation Myocardial Infarction. Clinical Medicine Insights. Cardiology. 2019. (13). C. 1179546819842804.
35. Kuro-o M. [и др.]. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997 390:6655. 1997. № 6655 (390). C. 45–51.
36. Kurosu H. [и др.]. Suppression of Aging in Mice by the Hormone Klotho. Science (New York, N.Y.). 2005. № 5742 (309). C. 1829.
37. Ky B. [и др.]. High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure. Circulation. Heart failure. 2010. № 2 (4). C. 180.
38. Ky B. [и др.]. High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure. Circ Heart Fail. 2011. (4). C. 180–187.
39. Li J. [и др.]. A Review of Novel Cardiac Biomarkers in Acute or Chronic Cardiovascular Diseases: The Role of Soluble ST2 (sST2), Lipoprotein-Associated Phospholipase A2 (Lp-PLA2), Myeloperoxidase (MPO), and Procalcitonin (PCT). Disease Markers. 2021. (2021). C. 6258865.
40. McDonagh T.A. [и др.]. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2021. № 36 (42). C. 3599–3726.
41. Morrow D.A. [и др.]. Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial.
42. Mueller C. [и др.]. Inflammation and long-term mortality in acute congestive heart failure. American Heart Journal. 2006. № 4 (151). C. 845–850.
43. Oztas E. [и др.]. Can Serum ST2 Levels Be Used as a Marker of Fibrosis in Chronic Hepatitis B Infection? Medicine. 2015. № 47 (94). C. e1889.
44. Pandey A. [и др.]. Physical Activity, Fitness, and Obesity in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure. 2018. № 12 (6). C. 975–982.
45. Pascual-Figal D.A. [и др.]. Soluble ST2 for Predicting Sudden Cardiac Death in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction. Journal of the American College of Cardiology. 2009. № 23 (54). C. 2174–2179.
46. Pascual-Figal D.A. [и др.]. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. European Journal of Heart Failure. 2011. № 7 (13). C. 718–725.
47. Pascual-Figal D.A. [и др.]. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. European Journal of Heart Failure. 2011. № 7 (13). C. 718–725.
48. Ragusa R. [и др.]. Time-course of circulating cardiac and inflammatory biomarkers after Ventricular Assist Device implantation: Comparison between paediatric and adult patients. Clinica Chimica Acta. 2018. (486). C. 88–93.
49. Riccardi M. [и др.]. Soluble ST2 in Heart Failure: A Clinical Role beyond B-Type Natriuretic Peptide. Journal of Cardiovascular Development and Disease. 2023. № 11 (10). C. 468.
50. Sciatti E. [и др.]. Prognostic Value of sST2 in Heart Failure. Journal of Clinical Medicine. 2023. № 12 (12). C. 3970.
51. Tominaga S. ichi Murine mRNA for the β-subunit of integrin is increased in BALB/c-3T3 cells entering the G1 phase from the G0 state. FEBS Letters. 1988. № 2 (238). C. 315–319.
52. Tsigkou V. [и др.]. The Predictive Role for ST2 in Patients with Acute Coronary Syndromes and Heart Failure. Current Medicinal Chemistry. 2019. № 27 (27). C. 4479–4493.
53. Tsutsui H. [и др.]. Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society. Journal of Cardiac Failure. 2023. № 5 (29). C. 787–804.
54. Villacorta H., Maisel A. S. Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure. Arquivos Brasileiros de Cardiologia. 2016. № 2 (106). C. 145.
55. Wang W. [и др.]. Cellular crosstalk in organotypic vasculature: mechanisms of diabetic cardiorenal complications and SGLT2i responses. Cardiovascular Diabetology. 2025. № 1 (24). C. 90.
56. Weinberg E.O. [и др.]. Expression and Regulation of ST2, an Interleukin-1 Receptor Family Member, in Cardiomyocytes and Myocardial Infarction. Circulation. 2002. № 23 (106). C. 2961.
57. Weinberg E.O. [и др.]. Identification of Serum Soluble ST2 Receptor as a Novel Heart Failure Biomarker 2003.
58. Yan X. [и др.]. The sST2 level is an independent influencing factor associated with atrial fibrillation in heart failure patients: a case-control study. Journal of Thoracic Disease. 2022. № 5 (14). C. 1578–1587.
59. Zhang J. [и др.]. Soluble ST2 in coronary artery disease: Clinical biomarkers and treatment guidance. Frontiers in Cardiovascular Medicine. 2022. (9). C. 924461.
Количество просмотров: 58
Категория статей:
Обзор литературы
Библиографическая ссылка
Kozhabayeva A.D., Mansurova J.A., Zhunuspekova A.S., Orekhov A.Yu., Kassymova A.A., Ashirov B.A., Smailova Zh.К., Kapakova M.A., Urazalina N.M., Karazhanova L.K. The SST2 biomarker as a predictor of adverse clinical outcomes in heart failure. Literature review // Nauka i Zdravookhranenie [Science & Healthcare]. 2025. Vol.27 (3), pp. 227-235. doi 10.34689/SH.2025.27.3.024Похожие публикации:
RADIATION EXPOSURE IN THE SEMIPALATINSK REGION: TRANSGENERATIONAL RISKS AND DOSIMETRY APPROACHES
TRENDS AND PATTERNS OF MALE REPRODUCTIVE SYSTEM DISEASES IN THE CONTEXT OF MEDICAL AND DEMOGRAPHIC INDICATORS. LITERATURE REVIEW
INFECTIOUS COMPLICATIONS OF UROLOGICAL INTERVENTIONS FOR UROLITHIASIS. LITERATURE REVIEW
PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE AS A GLOBAL HEALTH PROBLEM
THE QUALITY OF LIFE OF PATIENTS WITH COPD. LITERATURE REVIEW